Close Menu

NEW YORK (GenomeWeb) – Agendia announced today that its MammaPrint 70-gene signature breast cancer recurrence risk test has received positive coverage decisions from Aetna, Cigna, and UnitedHealthcare.

According to Agendia, the three insurers cover more than 85 million people in the US and internationally.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A genetic alteration appears to increase heart failure risk among people of African descent, according to the Washington Post.

Gene editing could be an issue competitive sports need to address soon, four researchers from Arizona State University write at Slate.

In his look back at the past decade, BuzzFeed News' Peter Aldhous writes that direct-to-consumer genetic testing has led to "Facebook for genes."

In Nature this week: genetic "clock" that can predict the lifespans of vertebrates, new assembler called wtdbg2, and more.

Dec
19
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.